US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CG Oncology Inc.

63.96

-0.6600-1.02%

Post-market: 64.560.6000+0.94%17:11 EDT

Volume:957.76K

Turnover:61.34M

Market Cap:5.40B

PE:-30.71

High:65.20

Open:64.62

Low:63.14

Close:64.62

52wk High:69.35

52wk Low:14.80

Shares:84.44M

Float Shares:67.76M

Volume Ratio:0.90

T/O Rate:1.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0826

EPS(LYR):-2.0826

ROE:-21.67%

ROA:-15.42%

PB:7.18

PE(LYR):-30.71

Loading ...

Overview Company News Filings

CG Oncology to Share Data for Investigational Bladder Cancer Therapy Nearly a Year Early

MT Newswires Live

CG Oncology to Report PIVOT-006 Phase 3 Topline Data for Intermediate-Risk NMIBC in First Half of 2026

CG Oncology Inc - Expects Phase 3 Pivot-006 Data in 1H 2026

THOMSON REUTERS

CG Oncology Provides Updated Timeline for Pivot-006 Phase 3 Topline Data in Intermediate-Risk Nmibc

THOMSON REUTERS

BofA Adjusts Price Target on CG Oncology to $62 From $60, Maintains Buy Rating

MT Newswires Live

CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed

Simply Wall St.

SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Initiated at Outperform by Wedbush

Wedbush Initiates CG Oncology at Outperform With $70 Price Target

MT Newswires Live

BRIEF-CG Oncology Inc - Announced Topline Data From Bond-003 Cohort P And First Results From Core-008 Cohort A

CG Oncology Inc - Bond-003 Cohort P Trial Shows Encouraging Hg-Efs and Well-Tolerated Safety Profile

THOMSON REUTERS

CG Oncology Reports Promising Results for Cretostimogene in High-Risk Bladder Cancer Trial

A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements

Simply Wall St.

CG Oncology Inc. Files Initial Statement of Beneficial Ownership for Director Christina Rossi

CG Oncology Appoints Christina Rossi to Board as Simone Song Resigns

CG Oncology Announces New Board Member and Board Transition

CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials

CG Oncology Inc. Files Initial Beneficial Ownership Statement for Officer James M. DeTore

CG Oncology Initiated at Buy by Truist Securities

CG Oncology Director Leonard E. Post Reports Sale of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CGON/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGON","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":63.96,"timestamp":1774900800000,"preClose":64.62,"halted":0,"volume":957757,"hourTrading":{"tag":"盘后","latestPrice":64.56,"preClose":63.96,"latestTime":"17:11 EDT","volume":35451,"amount":2267819.315,"timestamp":1774905060402,"change":0.6,"changeRate":0.009381,"amplitude":0.009381},"delay":0,"changeRate":-0.010213556174559017,"floatShares":67764900,"shares":84435200,"eps":-2.082636,"marketStatus":"Not Yet Opened","change":-0.66,"latestTime":"03-30 16:00:00 EDT","open":64.62,"high":65.2,"low":63.14,"amount":61337976.34352001,"amplitude":0.031879,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.082636,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774944000000},"marketStatusCode":0,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":64.62,"preHourTrading":{"tag":"盘前","latestPrice":65.1,"preClose":64.62,"latestTime":"09:15 EDT","volume":121,"amount":7844.958770000001,"timestamp":1774876541761,"change":0.48,"changeRate":0.007428,"amplitude":0.029248},"postHourTrading":{"tag":"盘后","latestPrice":64.56,"preClose":63.96,"latestTime":"17:11 EDT","volume":35451,"amount":2267819.315,"timestamp":1774905060402,"change":0.6,"changeRate":0.009381,"amplitude":0.009381},"volumeRatio":0.896479,"impliedVol":0.771,"impliedVolPercentile":0.8327},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","floatShares":67764900,"roa":"-15.42%","roe":"-21.67%","lyrEps":-2.082636,"volumeRatio":0.896479,"shares":84435200,"dividePrice":0,"high":65.2,"amplitude":0.031879,"preClose":64.62,"low":63.14,"week52Low":14.8,"pbRate":"7.18","psRate":"1336.75","week52High":69.35,"institutionHeld":0,"latestPrice":63.96,"eps":-2.082636,"divideRate":0,"volume":957757,"delay":0,"ttmEps":-2.082636,"open":64.62,"prevYearClose":41.52,"prevWeekClose":64.62,"prevMonthClose":58.8,"prevQuarterClose":41.52,"fiveDayClose":64.96,"twentyDayClose":57.76,"sixtyDayClose":41.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGON\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-27","symbol":"CGON","fiscalQuarterEnding":"2025/12","expectedEps":-0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1772168400000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-11-14","symbol":"CGON","fiscalQuarterEnding":"2025/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2025-08-08","symbol":"CGON","fiscalQuarterEnding":"2025/06","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.54},{"market":"US","date":"2025-05-13","symbol":"CGON","fiscalQuarterEnding":"2025/03","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-03-28","symbol":"CGON","fiscalQuarterEnding":"2024/12","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGON\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGON\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":15,"updateTime":1765684800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CGON\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CGON","date":"2026-03-27","current":-30.71108,"percent":0.340952,"low":-77.942097,"twenty":-43.120267,"median":-28.978972,"eighty":-20.155362,"high":-13.496527,"avg":-32.819864,"sd":14.010357,"marketCap":5629294784},"quantilePoints":[{"date":"2024-01-26","current":-62.124194,"twenty":-62.124194,"median":-62.124194,"eighty":-62.124194,"marketCap":2539823423},{"date":"2024-02-02","current":-61.712969,"twenty":-61.712969,"median":-60.379514,"eighty":-59.355029,"marketCap":2523011292},{"date":"2024-02-09","current":-63.452965,"twenty":-62.124194,"median":-60.590915,"eighty":-59.355029,"marketCap":2594147579},{"date":"2024-02-16","current":-77.177799,"twenty":-70.608092,"median":-61.918582,"eighty":-60.168112,"marketCap":3155259972},{"date":"2024-02-23","current":-75.080046,"twenty":-72.448911,"median":-64.672589,"eighty":-60.20714,"marketCap":3069497532},{"date":"2024-03-01","current":-72.705845,"twenty":-73.870179,"median":-70.608092,"eighty":-60.516111,"marketCap":2972433066},{"date":"2024-03-08","current":-64.818944,"twenty":-72.891228,"median":-69.827533,"eighty":-60.799064,"marketCap":2649992888},{"date":"2024-03-15","current":-60.493345,"twenty":-72.302556,"median":-67.469593,"eighty":-60.20714,"marketCap":2473149409},{"date":"2024-03-22","current":-66.867912,"twenty":-72.162706,"median":-65.355579,"eighty":-60.438055,"marketCap":2733760852},{"date":"2024-03-28","current":-56.207672,"twenty":-71.967566,"median":-64.762028,"eighty":-59.842879,"marketCap":2732086332},{"date":"2024-04-05","current":-51.752186,"twenty":-71.648838,"median":-63.50175,"eighty":-58.14191,"marketCap":2515518513},{"date":"2024-04-12","current":-54.631116,"twenty":-71.284577,"median":-62.382039,"eighty":-56.136384,"marketCap":2655454642},{"date":"2024-04-19","current":-48.420853,"twenty":-71.001624,"median":-61.712969,"eighty":-54.576279,"marketCap":2353592420},{"date":"2024-04-26","current":-49.627262,"twenty":-70.73168,"median":-60.54213,"eighty":-53.208102,"marketCap":2412232322},{"date":"2024-05-03","current":-54.151294,"twenty":-70.286112,"median":-60.183337,"eighty":-53.600185,"marketCap":2632131954},{"date":"2024-05-10","current":-35.176138,"twenty":-69.778748,"median":-59.371617,"eighty":-52.278619,"marketCap":2000537303},{"date":"2024-05-17","current":-36.289307,"twenty":-68.393255,"median":-58.232975,"eighty":-49.860318,"marketCap":2063845445},{"date":"2024-05-24","current":-35.140985,"twenty":-67.52163,"median":-57.330453,"eighty":-49.032283,"marketCap":1998538098},{"date":"2024-05-31","current":-40.179539,"twenty":-67.228921,"median":-56.207672,"eighty":-47.173317,"marketCap":2285090743},{"date":"2024-06-07","current":-40.894311,"twenty":-66.477632,"median":-55.878652,"eighty":-42.192617,"marketCap":2325741235},{"date":"2024-06-14","current":-40.788853,"twenty":-65.885708,"median":-55.522213,"eighty":-41.278647,"marketCap":2319743621},{"date":"2024-06-21","current":-37.625109,"twenty":-65.85969,"median":-54.631116,"eighty":-40.788853,"marketCap":2139815216},{"date":"2024-06-28","current":-35.445642,"twenty":-65.443392,"median":-54.494024,"eighty":-40.683395,"marketCap":2015864537},{"date":"2024-07-05","current":-36.125261,"twenty":-64.796178,"median":-54.151294,"eighty":-39.560851,"marketCap":2054515824},{"date":"2024-07-12","current":-40.378738,"twenty":-64.675841,"median":-53.136814,"eighty":-38.206301,"marketCap":2296419569},{"date":"2024-07-15","current":-41.491907,"twenty":-64.64657,"median":-52.780375,"eighty":-38.236766,"marketCap":2359727711},{"date":"2024-08-02","current":-39.652248,"twenty":-64.6173,"median":-52.752957,"eighty":-38.267232,"marketCap":2255102676},{"date":"2024-08-09","current":-38.949194,"twenty":-63.924553,"median":-51.752186,"eighty":-38.000071,"marketCap":2215118586},{"date":"2024-08-16","current":-40.572681,"twenty":-63.472479,"median":-49.956283,"eighty":-38.105529,"marketCap":2307449488},{"date":"2024-08-23","current":-42.377221,"twenty":-62.965116,"median":-49.723226,"eighty":-38.189896,"marketCap":2410077328},{"date":"2024-08-30","current":-43.2618,"twenty":-62.33047,"median":-48.934948,"eighty":-38.276606,"marketCap":2460385093},{"date":"2024-09-06","current":-44.299706,"twenty":-62.063778,"median":-48.270052,"eighty":-38.375033,"marketCap":2519412871},{"date":"2024-09-13","current":-41.079839,"twenty":-61.869081,"median":-45.980618,"eighty":-38.588613,"marketCap":2336292606},{"date":"2024-09-20","current":-46.127835,"twenty":-61.368222,"median":-44.806865,"eighty":-38.861791,"marketCap":2623382252},{"date":"2024-09-27","current":-43.379744,"twenty":-60.747027,"median":-44.736098,"eighty":-39.046612,"marketCap":2467092795},{"date":"2024-10-04","current":-42.412604,"twenty":-60.551887,"median":-44.517902,"eighty":-39.324835,"marketCap":2412089639},{"date":"2024-10-11","current":-40.667036,"twenty":-60.382766,"median":-44.458898,"eighty":-39.52313,"marketCap":2312815649},{"date":"2024-10-18","current":-43.356155,"twenty":-60.203473,"median":-44.063818,"eighty":-39.574912,"marketCap":2465751255},{"date":"2024-10-25","current":-42.990529,"twenty":-60.177247,"median":-43.698192,"eighty":-39.657154,"marketCap":2444957379},{"date":"2024-10-31","current":-42.837202,"twenty":-60.01213,"median":-43.662809,"eighty":-39.673778,"marketCap":2436237366},{"date":"2024-11-08","current":-46.068863,"twenty":-59.381569,"median":-43.651015,"eighty":-39.804577,"marketCap":2620028401},{"date":"2024-11-15","current":-32.980568,"twenty":-59.208121,"median":-43.63922,"eighty":-39.654701,"marketCap":2400853462},{"date":"2024-11-22","current":-30.044833,"twenty":-58.542987,"median":-43.538968,"eighty":-38.997903,"marketCap":2187143689},{"date":"2024-11-29","current":-32.283796,"twenty":-58.232975,"median":-43.444613,"eighty":-38.328163,"marketCap":2350131206},{"date":"2024-12-06","current":-31.17825,"twenty":-58.005312,"median":-43.379744,"eighty":-38.000071,"marketCap":2269651893},{"date":"2024-12-13","current":-26.821099,"twenty":-57.745125,"median":-43.279491,"eighty":-37.543086,"marketCap":1952468717},{"date":"2024-12-20","current":-26.031423,"twenty":-56.915781,"median":-43.120267,"eighty":-36.394765,"marketCap":1894983493},{"date":"2024-12-27","current":-27.044066,"twenty":-56.349294,"median":-43.061296,"eighty":-36.125261,"marketCap":1968699839},{"date":"2025-01-03","current":-26.914002,"twenty":-56.207672,"median":-43.037707,"eighty":-35.33784,"marketCap":1959231684},{"date":"2025-01-10","current":-28.298257,"twenty":-56.136384,"median":-42.978735,"eighty":-34.953504,"marketCap":2059999900},{"date":"2025-01-17","current":-27.034776,"twenty":-55.969133,"median":-42.872585,"eighty":-33.374909,"marketCap":1968023542},{"date":"2025-01-24","current":-32.158189,"twenty":-55.840266,"median":-42.689773,"eighty":-32.852839,"marketCap":2340987506},{"date":"2025-01-31","current":-31.530712,"twenty":-55.653821,"median":-42.565931,"eighty":-32.283796,"marketCap":2295309701},{"date":"2025-02-07","current":-31.405216,"twenty":-55.437216,"median":-42.394913,"eighty":-32.036945,"marketCap":2286174140},{"date":"2025-02-14","current":-29.805151,"twenty":-55.004006,"median":-42.206678,"eighty":-31.677123,"marketCap":2169695737},{"date":"2025-02-21","current":-29.512328,"twenty":-54.631116,"median":-41.999801,"eighty":-31.530712,"marketCap":2148379428},{"date":"2025-02-28","current":-25.768383,"twenty":-54.494024,"median":-41.775708,"eighty":-31.373843,"marketCap":1875835192},{"date":"2025-03-07","current":-28.226,"twenty":-54.39406,"median":-41.609082,"eighty":-31.094637,"marketCap":2054739928},{"date":"2025-03-14","current":-27.138374,"twenty":-54.151294,"median":-41.292708,"eighty":-30.560445,"marketCap":1975565066},{"date":"2025-03-21","current":-29.020804,"twenty":-53.671473,"median":-41.068045,"eighty":-30.21301,"marketCap":2112598481},{"date":"2025-03-28","current":-28.173711,"twenty":-53.493253,"median":-40.922206,"eighty":-29.826066,"marketCap":2050933444},{"date":"2025-04-04","current":-16.223536,"twenty":-52.780375,"median":-40.788853,"eighty":-29.478125,"marketCap":1428303862},{"date":"2025-04-11","current":-15.26259,"twenty":-52.725539,"median":-40.592885,"eighty":-29.073094,"marketCap":1343703153},{"date":"2025-04-17","current":-17.504797,"twenty":-52.648767,"median":-40.36956,"eighty":-28.807616,"marketCap":1541104808},{"date":"2025-04-25","current":-18.630229,"twenty":-51.927664,"median":-39.710836,"eighty":-28.715432,"marketCap":1640186719},{"date":"2025-05-02","current":-24.014988,"twenty":-51.631545,"median":-39.587801,"eighty":-28.276198,"marketCap":2114255557},{"date":"2025-05-09","current":-20.891121,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"marketCap":1839233409},{"date":"2025-05-16","current":-18.305859,"twenty":-49.931606,"median":-38.624431,"eighty":-27.822323,"marketCap":1932311557},{"date":"2025-05-23","current":-18.60193,"twenty":-49.805481,"median":-38.19927,"eighty":-27.481395,"marketCap":1963563934},{"date":"2025-05-30","current":-18.941329,"twenty":-49.745161,"median":-38.000071,"eighty":-27.137812,"marketCap":1999389828},{"date":"2025-06-06","current":-19.230179,"twenty":-49.665648,"median":-37.795014,"eighty":-26.986466,"marketCap":2029879952},{"date":"2025-06-13","current":-19.136302,"twenty":-49.503879,"median":-37.543086,"eighty":-26.644583,"marketCap":2019970662},{"date":"2025-06-20","current":-18.977435,"twenty":-49.032283,"median":-37.168124,"eighty":-26.449487,"marketCap":2003201094},{"date":"2025-06-27","current":-18.825789,"twenty":-48.437304,"median":-36.365471,"eighty":-26.243173,"marketCap":1987193779},{"date":"2025-07-03","current":-19.425152,"twenty":-48.360533,"median":-36.207284,"eighty":-25.994262,"marketCap":2050460785},{"date":"2025-07-11","current":-19.576798,"twenty":-47.916755,"median":-36.101826,"eighty":-24.54782,"marketCap":2066468099},{"date":"2025-07-18","current":-20.551667,"twenty":-47.047797,"median":-35.158562,"eighty":-23.322415,"marketCap":2169372265},{"date":"2025-07-25","current":-18.876337,"twenty":-46.758067,"median":-34.836328,"eighty":-20.953178,"marketCap":1992529551},{"date":"2025-08-01","current":-19.273506,"twenty":-46.459723,"median":-33.67043,"eighty":-19.630235,"marketCap":2034453470},{"date":"2025-08-08","current":-17.583734,"twenty":-46.116041,"median":-33.231407,"eighty":-19.436706,"marketCap":1856086249},{"date":"2025-08-15","current":-15.454183,"twenty":-46.05471,"median":-32.738157,"eighty":-19.425152,"marketCap":1979387202},{"date":"2025-08-22","current":-15.466089,"twenty":-45.994601,"median":-32.283796,"eighty":-19.321744,"marketCap":1980912154},{"date":"2025-08-29","current":-15.90364,"twenty":-45.910989,"median":-32.179105,"eighty":-19.234852,"marketCap":2036954126},{"date":"2025-09-05","current":-18.418814,"twenty":-45.632471,"median":-32.073773,"eighty":-19.17963,"marketCap":2359100156},{"date":"2025-09-12","current":-19.740397,"twenty":-45.219668,"median":-31.708497,"eighty":-19.194072,"marketCap":2528369785},{"date":"2025-09-19","current":-23.109837,"twenty":-44.877631,"median":-31.635292,"eighty":-19.201294,"marketCap":2959931094},{"date":"2025-09-26","current":-21.716818,"twenty":-44.736098,"median":-31.530712,"eighty":-19.230179,"marketCap":2781511754},{"date":"2025-10-03","current":-23.725981,"twenty":-44.665332,"median":-31.426132,"eighty":-19.253545,"marketCap":3038847340},{"date":"2025-10-10","current":-26.467372,"twenty":-44.523799,"median":-31.321553,"eighty":-19.273506,"marketCap":3389967451},{"date":"2025-10-17","current":-24.913619,"twenty":-44.512005,"median":-31.136443,"eighty":-19.29517,"marketCap":3190961264},{"date":"2025-10-24","current":-24.991009,"twenty":-44.50021,"median":-30.85309,"eighty":-19.316833,"marketCap":3200873450},{"date":"2025-10-31","current":-25.28271,"twenty":-44.458898,"median":-30.516316,"eighty":-19.341386,"marketCap":3238234765},{"date":"2025-11-07","current":-23.627755,"twenty":-44.299706,"median":-30.278194,"eighty":-19.345718,"marketCap":3026266489},{"date":"2025-11-14","current":-22.478812,"twenty":-44.252528,"median":-29.998382,"eighty":-19.366088,"marketCap":2879108658},{"date":"2025-11-21","current":-21.67833,"twenty":-43.981257,"median":-29.826066,"eighty":-19.425152,"marketCap":3283920147},{"date":"2025-11-28","current":-23.877581,"twenty":-43.896338,"median":-29.564618,"eighty":-19.425152,"marketCap":3617071466},{"date":"2025-12-05","current":-23.819005,"twenty":-43.743011,"median":-29.395876,"eighty":-19.425152,"marketCap":3608198186},{"date":"2025-12-12","current":-22.157586,"twenty":-43.700551,"median":-29.125384,"eighty":-19.430929,"marketCap":3356519708},{"date":"2025-12-19","current":-20.235238,"twenty":-43.669886,"median":-28.978972,"eighty":-19.432373,"marketCap":3065314802},{"date":"2025-12-26","current":-21.374801,"twenty":-43.648656,"median":-28.805205,"eighty":-19.445371,"marketCap":3237940425},{"date":"2026-01-02","current":-22.10966,"twenty":-43.629785,"median":-28.780272,"eighty":-19.471368,"marketCap":3349259752},{"date":"2026-01-09","current":-22.327988,"twenty":-43.592043,"median":-28.623402,"eighty":-19.508919,"marketCap":3382332885},{"date":"2026-01-16","current":-28.260107,"twenty":-43.542507,"median":-28.614819,"eighty":-19.546469,"marketCap":4280954119},{"date":"2026-01-23","current":-29.740475,"twenty":-43.516559,"median":-28.759356,"eighty":-19.598802,"marketCap":4505206097},{"date":"2026-01-30","current":-28.446485,"twenty":-43.476458,"median":-28.670137,"eighty":-19.697535,"marketCap":4309187282},{"date":"2026-02-06","current":-26.199308,"twenty":-43.389179,"median":-28.638782,"eighty":-19.761114,"marketCap":3968776006},{"date":"2026-02-13","current":-27.487973,"twenty":-43.379744,"median":-28.51571,"eighty":-19.844698,"marketCap":4163988159},{"date":"2026-02-20","current":-30.044003,"twenty":-43.379744,"median":-28.606237,"eighty":-19.847552,"marketCap":4551185819},{"date":"2026-02-27","current":-29.878927,"twenty":-43.356155,"median":-28.662149,"eighty":-19.899759,"marketCap":4526179303},{"date":"2026-03-06","current":-31.661561,"twenty":-43.297183,"median":-28.73844,"eighty":-19.924942,"marketCap":5097353024},{"date":"2026-03-13","current":-33.025153,"twenty":-43.2618,"median":-28.79073,"eighty":-20.020192,"marketCap":5316884544},{"date":"2026-03-20","current":-34.540838,"twenty":-43.202828,"median":-28.86184,"eighty":-20.05591,"marketCap":5560902272},{"date":"2026-03-27","current":-34.96565,"twenty":-43.120267,"median":-28.978972,"eighty":-20.155362,"marketCap":5629294784}],"updateTime":1774933272895},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGON\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602797163","title":"CG Oncology to Share Data for Investigational Bladder Cancer Therapy Nearly a Year Early","url":"https://stock-news.laohu8.com/highlight/detail?id=2602797163","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602797163?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:57","pubTimestamp":1767967035,"startTime":"0","endTime":"0","summary":"CG Oncology  said Friday it has sped up the timeline for the topline data readout of the phase 3 clinical trial of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer to H1 2026, nearly a year ahead of schedule because of early enrollment of 360 patients.Chairman and Chief Executive Arthur Kuan said the company hopes to bring forward a potential indication for cretostimogene,  an investigational immunotherapy, as a treatment for non-muscle bladder cancer.Shares of the company were up over 6% in recent premarket activity Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B64PRP62.GBP","BK4135","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","CGON","BK4139","CG"],"gpt_icon":0},{"id":"2602937602","title":"CG Oncology to Report PIVOT-006 Phase 3 Topline Data for Intermediate-Risk NMIBC in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602937602","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602937602?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965425,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has announced an expedited timeline for the topline data readout of its Phase 3 PIVOT-006 clinical trial. The study evaluates adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer . Topline data from this randomized, open-label registrational trial are now expected in the first half of 2026, nearly one year ahead of schedule due to rapid enrollment across more than 90 sites. The results have not yet been presented and will be available in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDLb3KHRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139","BK4588","BK4112","LU2210149790.SGD","LU0314104364.USD","NDAQ","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014013.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4585","IE00B3QW5Z07.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2602537606","title":"CG Oncology Inc - Expects Phase 3 Pivot-006 Data in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602537606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602537606?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9MH8SQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2602376031","title":"CG Oncology Provides Updated Timeline for Pivot-006 Phase 3 Topline Data in Intermediate-Risk Nmibc","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376031?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9MH8SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2601164918","title":"BofA Adjusts Price Target on CG Oncology to $62 From $60, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601164918","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601164918?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:38","pubTimestamp":1767713909,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has an average rating of buy and mean price target of $70.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2592139541","title":"CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139541","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592139541?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:17","pubTimestamp":1766179072,"startTime":"0","endTime":"0","summary":"CG Oncology recently reported topline data from its BOND-003 and CORE-004 trials of investigational therapy cretostimogene in non-muscle invasive bladder cancer, showing encouraging efficacy measures, a consistent safety profile, and largely localized, low-grade bladder-related adverse events in patients across multiple high-risk settings.\nThe data, which will be featured as late-breaking abstracts at the Society of Urologic Oncology meeting, highlight high complete response rates in...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B64PRP62.GBP","BK4135","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","CGON","BK4139","AI","CG"],"gpt_icon":0},{"id":"2592909219","title":"SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909219","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909219?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062800,"startTime":"0","endTime":"0","summary":"Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on Febru","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207681/0/en/SUO-CTC-and-CG-Oncology-Announce-the-Second-Annual-Non-Muscle-Invasive-Bladder-Cancer-NMIBC-Research-Fellowship-Award.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4135","CG","IE00B3QW5Z07.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2590514596","title":"CG Oncology Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2590514596","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590514596?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:28","pubTimestamp":1765463280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 09:28 ET (14:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","CGON"],"gpt_icon":0},{"id":"2590182085","title":"Wedbush Initiates CG Oncology at Outperform With $70 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590182085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590182085?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:03","pubTimestamp":1765454590,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has an average rating of buy and mean price target of $70.77, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGON","CG"],"gpt_icon":0},{"id":"2589389013","title":"BRIEF-CG Oncology Inc - Announced Topline Data From Bond-003 Cohort P And First Results From Core-008 Cohort A","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389013","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589389013?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:38","pubTimestamp":1764941922,"startTime":"0","endTime":"0","summary":"BRIEF-CG Oncology Inc - Announced Topline Data From Bond-003 Cohort P And First Results From Core-008 Cohort ADec 5 (Reuters) - CG Oncology Inc CGON.O:CG ONCOLOGY INC - ANNOUNCED TOPLINE DATA FROM BON","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2589890949","title":"CG Oncology Inc - Bond-003 Cohort P Trial Shows Encouraging Hg-Efs and Well-Tolerated Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890949?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:36","pubTimestamp":1764941789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0S6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2589989068","title":"CG Oncology Reports Promising Results for Cretostimogene in High-Risk Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589989068","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589989068?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941411,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has announced topline results from the BOND-003 Cohort P and initial findings from the CORE-008 Cohort A clinical trials evaluating cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer . The results, presented at the Society of Urologic Oncology  26th Annual Meeting, highlighted promising efficacy and a favorable safety profile for cretostimogene. In the BOND-003 Cohort P study involving patients with BCG-unresponsive  papillary-only NMIBC, high-grade event-free survival  rates at 3, 6, and 9 months were reported at 95.7%, 84.6%, and 80.4%, respectively. No Grade 3 or higher treatment-related adverse events or deaths were observed, and no patients required radical cystectomy or progressed to muscle invasive bladder cancer. The CORE-008 Cohort A data in high-risk BCG-nave NMIBC demonstrated an 88% complete response rate and a favorable safety profile with optimized administration. Enrollment has been completed for the BOND-003 Cohort P stud","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL2GY28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","CGON","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","BK4139","BK4588","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2588484718","title":"A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements","url":"https://stock-news.laohu8.com/highlight/detail?id=2588484718","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588484718?lang=en_us&edition=fundamental","pubTime":"2025-12-01 01:10","pubTimestamp":1764522635,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) is making headlines after announcing two late-breaking podium presentations on topline clinical trial results for cretostimogene at the upcoming Society of Urologic Oncology Annual Meeting. This news has sparked renewed investor interest.\nSee our latest analysis for CG Oncology.\nMomentum has clearly been building for CG Oncology, especially as topline clinical data and boardroom changes have turned heads. The share price return over the past 90 days stands out at 67.2%,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","CG","CGON","IE00B64PRP62.GBP","DCF","BK4135"],"gpt_icon":0},{"id":"2586260230","title":"CG Oncology Inc. Files Initial Statement of Beneficial Ownership for Director Christina Rossi","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260230?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:15","pubTimestamp":1764191738,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Christina Rossi as the beneficial owner in her role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL9Ckcvj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2586251683","title":"CG Oncology Appoints Christina Rossi to Board as Simone Song Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251683","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251683?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:00","pubTimestamp":1764158433,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has appointed Christina Rossi to its Board of Directors. Simone Song has resigned from the Board, effective November 22, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL8JjVQ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","NDAQ","BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","BK4112","LU2210149790.SGD","CGON"],"gpt_icon":0},{"id":"2586251615","title":"CG Oncology Announces New Board Member and Board Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251615","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251615?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:00","pubTimestamp":1764158400,"startTime":"0","endTime":"0","summary":"- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov.  26, 2025  (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/26/3194997/0/en/CG-Oncology-Announces-New-Board-Member-and-Board-Transition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU1244550221.USD","LU1244550494.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1668664300.SGD","LU1720051017.SGD","BK4516","LU0557290698.USD","LU2357305700.SGD","LU1548497426.USD","IE00B3QW5Z07.USD","BK4127","LU1732799900.SGD","LU0006306889.USD","BK4504","LU2028103732.USD","LU1989772840.SGD","BK4135","LU0320765646.SGD","CGON","BK4585","LU0528227936.USD","LU2089283258.USD","LU2023251221.USD","IE00B64PRP62.GBP","CG","BK4588","LU1989772923.USD","LU0882574139.USD","LU0158827781.USD","LU1732800096.USD","LU0267386448.USD","LU0314104364.USD","BK4581","LU1244550577.SGD","LU1720051108.HKD","LU1791710400.SGD","LU0106831901.USD","LU1363072403.SGD","LU1074936037.SGD","BK4139","LU2347655156.SGD","LU1162221912.USD","LU2111349929.HKD","LU2133065610.SGD","LU2271345857.HKD","IE00BGHQF748.EUR","LU0106261372.USD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2586879409","title":"CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2586879409","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586879409?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:05","pubTimestamp":1764104730,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has announced that new clinical results on cretostimogene grenadenorepvec, an investigational intravesical therapy for non-muscle invasive bladder cancer , will be presented at the Society of Urologic Oncology  26th Annual Meeting, scheduled for December 2-5, 2025, in Phoenix, Arizona. Two late-breaking podium presentations will highlight topline results from BOND-003 Cohort P, a study in high-risk, papillary-only, BCG-unresponsive NMIBC, and first results from CORE-008 Cohort A, a phase 2 study in high-risk, BCG-nave NMIBC with carcinoma in situ. Additionally, three posters will provide updates, including 24-month outcomes from BOND-003 Cohort C and ongoing trial progress and program designs related to cretostimogene grenadenorepvec. Results from these studies are scheduled to be presented during the SUO meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6c7cL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","IE00B3QW5Z07.USD","BK4588","BK4139","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2586900094","title":"CG Oncology Inc. Files Initial Beneficial Ownership Statement for Officer James M. DeTore","url":"https://stock-news.laohu8.com/highlight/detail?id=2586900094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586900094?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:30","pubTimestamp":1764019850,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names James M. DeTore as the beneficial owner in his capacity as an officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3L5cw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2586227491","title":"CG Oncology Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2586227491","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586227491?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:05","pubTimestamp":1764007500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 13:05 ET (18:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","BK4135","CG","IE00B3QW5Z07.USD","CGON","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2584296668","title":"CG Oncology Director Leonard E. Post Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296668","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296668?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:30","pubTimestamp":1763501440,"startTime":"0","endTime":"0","summary":"Leonard E. Post, Director at CG Oncology Inc., reported a disposal of common shares of CG Oncology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLbvJZTv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CG Oncology Director Leonard E. Post Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":94,"code":"91000000","status":"200"}]}}